Monday, October 26, 2026 · Daily editionET --:--:--

United States1 robot tracked

Accuray

Accuray makes CyberKnife, which is at stage 5 of 5: regulator-cleared or mass market.

Website: accuray.com
Based in: United States
Latest milestone: 19 Aug 2026

01Robots

What Accuray makes

Each robot's stage is worked out from its dated, sourced milestones by the same published rules, whoever the maker is.

CyberKnifeMedical · Robotic radiation treatmentStage 5 of 5 · Regulator-cleared or mass marketCyberKnife is a robot that aims strong beams of X-rays at tumors to destroy them, guided by live images of the patient. Treatment usually takes one to five sessions, with no cutting.Sold to hospitals and cancer centers; Accuray said more than 200 were installed by mid-2010. Current models are the CyberKnife S7 and M6.The full record

02Track record

Every dated event

19 Aug 2026Setback
Accuray spent $16.2 million on restructuring in its 2026 fiscal year.
Accuray fiscal 2026 results (SEC filing), 19 Aug 2026
19 Aug 2026Setback
Accuray's new product orders fell to $191.9 million in its 2026 fiscal year, from $288.0 million a year before. The figure covers all of Accuray's machines, not only CyberKnife.
Accuray fiscal 2026 results (SEC filing), 19 Aug 2026
14 Dec 2010Regulator
The FDA cleared a CyberKnife add-on through the 510(k) route that lets doctors treat lung tumors without first implanting small marker seeds.
AuntMinnie, 14 Dec 2010Company-reported
June 2010Milestone
Accuray marked its 200th CyberKnife installation.
MassDevice, 16 Aug 2010Company-reported
Nov 2001Regulator
The FDA cleared CyberKnife through the 510(k) route to treat tumors anywhere in the body where radiation is called for.
Medtech Insight (Citeline), 5 Nov 2001
1999Regulator
The FDA cleared CyberKnife to treat tumors in the head and neck.
Medtech Insight (Citeline), 5 Nov 2001

03Money

On the stock market

Accuray trades as ARAY on NASDAQ. Accuray investor FAQs

All robot stocks, funding and suppliers

Prices by TradingView, about 15 minutes delayed. Not investment advice.